CENTAURUS: A phase II trial of daratumumab monotherapy for intermediate/high-risk smoldering MM

Smoldering MM is an asymptomatic precursor to MM, with high-risk patients experiencing a substantial risk of progression to MM within 5 years of diagnosis.¹ Although active surveillance is currently the standard approach, early intervention strategies are being explored to assess their potential impact on disease progression.¹

The phase II CENTAURUS trial (NCT02316106; N = 123) evaluated daratumumab monotherapy in patients with intermediate/high-risk smoldering MM across three dosing regimens: long intense, intermediate, and short intense (n = 41 each).¹ All schedules included IV daratumumab at 16 mg/kg, delivered in 8-week cycles. The long and intermediate regimens extended to 20 cycles with optional extension periods, whilst the short intensive regimen was delivered in a single cycle once weekly.¹

Landgren et al.¹ published the final analysis from the CENTAURUS trial in Blood.